Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:31R Stock Latest News

Company AnnouncementsRevive Therapeutics Moves to Build Global Bucillamine Franchise in Biodefence and Rare Diseases1M ago

The FlyRevive Therapeutics to expand bucillamine IP, Orphan Drug portfolio1M ago
Company AnnouncementsRevive Therapeutics Moves to Settle Trade Debt Through Share Issuance2M ago
Company AnnouncementsRevive Therapeutics Sets Bucillamine-Led Strategy for Biodefence and Pandemic Countermeasures2M ago
The FlyRevive outlines strategy for biodefense, pandemic preparedness therapeutics2M ago

Revive Therapeutics reports results from DRDC bucillamine research study

The FlyRevive Therapeutics reports results from DRDC bucillamine research study2M ago

Company AnnouncementsRevive Therapeutics Grants 15.5 Million Stock Options to Key Team Members2M ago

Company AnnouncementsBlackRock Disclosure Confirms Significant Stake in Caledonia Mining3M ago

The FlyRevive expands bucillamine program across infectious diseases5M ago
Company AnnouncementsRevive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses7M ago
The FlyRevive Therapeutics announces North American patent filings for bucillamine7M ago
Company AnnouncementsRevive Therapeutics Updates on Nerve Agent Countermeasure Study10M ago

Revive Therapeutics provides update on nerve agent countmeasure study

The FlyRevive Therapeutics provides update on nerve agent countmeasure study10M ago

Company AnnouncementsRevive Therapeutics Updates on Nerve Agent Countermeasure Study11M ago

The FlyRevive Therapeutics says nerve agent countmeasure study ‘remains in progress’11M ago

Company AnnouncementsRevive Therapeutics Closes Second Tranche of Private Placement1y ago
Company AnnouncementsRevive Therapeutics Extends Private Placement to Support Therapeutic Programs1y ago
Company AnnouncementsRevive Therapeutics Completes First Tranche of Private Placement and Debt Settlement1y ago
Company AnnouncementsRevive Therapeutics Announces Private Placement and Debt Settlement Plan1y ago

Revive Therapeutics Updates on Nerve Agent Countermeasure Study

Company AnnouncementsRevive Therapeutics Updates on Nerve Agent Countermeasure Study1y ago

Company AnnouncementsRevive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence1y ago

The FlyRevive Therapeutics nears completion of nerve agent countermeasure study1y ago